Cargando…

Pharmacological treatment of osteoporosis in the oldest old

The incidence of osteoporotic fractures increases with age. Consequently, the global prevalence of osteoporotic fractures will increase with the aging of the population. In old age, osteoporosis is associated with a substantial burden in terms of morbidity and mortality. Nevertheless, osteoporosis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandenbroucke, A, Luyten, FP, Flamaing, J, Gielen, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505539/
https://www.ncbi.nlm.nih.gov/pubmed/28740372
http://dx.doi.org/10.2147/CIA.S131023
_version_ 1783249449569484800
author Vandenbroucke, A
Luyten, FP
Flamaing, J
Gielen, E
author_facet Vandenbroucke, A
Luyten, FP
Flamaing, J
Gielen, E
author_sort Vandenbroucke, A
collection PubMed
description The incidence of osteoporotic fractures increases with age. Consequently, the global prevalence of osteoporotic fractures will increase with the aging of the population. In old age, osteoporosis is associated with a substantial burden in terms of morbidity and mortality. Nevertheless, osteoporosis in old age continues to be underdiagnosed and undertreated. This may, at least partly, be explained by the fact that evidence of the antifracture efficacy of osteoporosis treatments comes mainly from randomized controlled trials in postmenopausal women with a mean age of 70–75 years. However, in the last years, subgroup analyses of these landmark trials have been published investigating the efficacy and safety of osteoporosis treatment in the very elderly. Based on this evidence, this narrative review discusses the pharmacological management of osteoporosis in the oldest old (≥80 years). Because of the high prevalence of calcium and/or vitamin D deficiency in old age, these supplements are essential in the management of osteoporosis in the elderly people. Adding antiresorptive or anabolic treatments or combinations, thereof, reduces the risk of vertebral fractures even more, at least in the elderly with documented osteoporosis. The reduction of hip fracture risk by antiresorptive treatments is less convincing, which may be explained by insufficient statistical power in some subanalyses and/or a higher impact of nonskeletal risk factors in the occurrence of hip fractures. Compared with younger individuals, a larger absolute risk reduction is observed in the elderly because of the higher baseline fracture risk. Therefore, the elderly will benefit more of treatment. In addition, current osteoporosis therapies also appear to be safe in the elderly. Although more research is required to further clarify the effect of osteoporosis drugs in the elderly, especially with respect to hip fractures, there is currently sufficient evidence to initiate appropriate treatment in the elderly with osteoporosis and osteoporotic fractures.
format Online
Article
Text
id pubmed-5505539
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55055392017-07-24 Pharmacological treatment of osteoporosis in the oldest old Vandenbroucke, A Luyten, FP Flamaing, J Gielen, E Clin Interv Aging Review The incidence of osteoporotic fractures increases with age. Consequently, the global prevalence of osteoporotic fractures will increase with the aging of the population. In old age, osteoporosis is associated with a substantial burden in terms of morbidity and mortality. Nevertheless, osteoporosis in old age continues to be underdiagnosed and undertreated. This may, at least partly, be explained by the fact that evidence of the antifracture efficacy of osteoporosis treatments comes mainly from randomized controlled trials in postmenopausal women with a mean age of 70–75 years. However, in the last years, subgroup analyses of these landmark trials have been published investigating the efficacy and safety of osteoporosis treatment in the very elderly. Based on this evidence, this narrative review discusses the pharmacological management of osteoporosis in the oldest old (≥80 years). Because of the high prevalence of calcium and/or vitamin D deficiency in old age, these supplements are essential in the management of osteoporosis in the elderly people. Adding antiresorptive or anabolic treatments or combinations, thereof, reduces the risk of vertebral fractures even more, at least in the elderly with documented osteoporosis. The reduction of hip fracture risk by antiresorptive treatments is less convincing, which may be explained by insufficient statistical power in some subanalyses and/or a higher impact of nonskeletal risk factors in the occurrence of hip fractures. Compared with younger individuals, a larger absolute risk reduction is observed in the elderly because of the higher baseline fracture risk. Therefore, the elderly will benefit more of treatment. In addition, current osteoporosis therapies also appear to be safe in the elderly. Although more research is required to further clarify the effect of osteoporosis drugs in the elderly, especially with respect to hip fractures, there is currently sufficient evidence to initiate appropriate treatment in the elderly with osteoporosis and osteoporotic fractures. Dove Medical Press 2017-07-06 /pmc/articles/PMC5505539/ /pubmed/28740372 http://dx.doi.org/10.2147/CIA.S131023 Text en © 2017 Vandenbroucke et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Vandenbroucke, A
Luyten, FP
Flamaing, J
Gielen, E
Pharmacological treatment of osteoporosis in the oldest old
title Pharmacological treatment of osteoporosis in the oldest old
title_full Pharmacological treatment of osteoporosis in the oldest old
title_fullStr Pharmacological treatment of osteoporosis in the oldest old
title_full_unstemmed Pharmacological treatment of osteoporosis in the oldest old
title_short Pharmacological treatment of osteoporosis in the oldest old
title_sort pharmacological treatment of osteoporosis in the oldest old
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505539/
https://www.ncbi.nlm.nih.gov/pubmed/28740372
http://dx.doi.org/10.2147/CIA.S131023
work_keys_str_mv AT vandenbrouckea pharmacologicaltreatmentofosteoporosisintheoldestold
AT luytenfp pharmacologicaltreatmentofosteoporosisintheoldestold
AT flamaingj pharmacologicaltreatmentofosteoporosisintheoldestold
AT gielene pharmacologicaltreatmentofosteoporosisintheoldestold